Skip to main content

Table 3 Distribution of comorbidities type among the study population with one comorbidity

From: Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice

  HIV+ patients
N = 251
HIV/HCV patients
N = 200
Chi-squared
Cardiovascular comorbiditiesa 164 [65.59%] 84 [42.00%] < 0.001
Neurocognitive impairmentsb 45 [17.99%] 27 [13.50%] > 0.050
HBV infection 25 [10.00%] 9 [4.50%] 0.032
Bone eventsc 7 [2.80%] 61 [30.51%] < 0.001
Renal impairmentsd 6 [2.41%] 4 [1.99%] > 0.050
Diabetes 3 [1.20%] 15 [7.50%] 0.001
  1. aCardiovascular (CDV) events, including hypertension, cardiovascular risk, atrial fibrillation, acute myocardial infarction
  2. bNeurocognitive impairments, including clinically evident HIV-related dementia, cerebral aneurysm
  3. cBone events, including osteoporosis, osteopenia, arthritis, bone fractures
  4. dRenal impairments, including calculosis, proteinuria from grade 2 to 3, and kidney failure